3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1/2
6
Phase 3
2
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
24
Genitourinary
8
Head & Neck
4
Gynecologic
4
Thoracic
3
Dermatologic
2
Other hematologic neoplasm
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Interventions
Dacarbazine
27
Nivolumab
26
pembrolizumab
22
Ipilimumab
20
3-ingenyl angelate
11
Interferon-alpha
10
Imiquimod
10
Temozolomide
9
trametinib
8
Vemurafenib
8
Photochemotherapy
8
Aminolevulinic Acid
8
methyl 5-aminolevulinate
7
dabrafenib
7
cemiplimab
7
aldesleukin
7
Introns
7
Surgical Procedures, Operative
6
Radiotherapy
6
Interferon alpha-2
6
Fluorouracil
6
Paclitaxel
5
Melphalan
5
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
binimetinib
4
Specimen Handling
4
Opdualag
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
lenvatinib
×
Dermatologic
×
Clear all
NCT03820986
2026-02-09
LEAP-003
Merck Sharp & Dohme LLC
Phase 3
Completed
674 enrolled
21 charts
NCT04889118
2025-12-23
LEAP-003
Merck Sharp & Dohme LLC
Phase 3
Completed
131 enrolled
16 charts